Hyperhomocysteinemia as a risk factor of cardiovascular disease in chronic renal failure;Hiperhomocysteinemia jako czynnik ryzyka powikłań sercowo-naczyniowych u chorych z przewlekła̧ niewydolnościa̧ nerek

Polskie Archiwum Medycyny Wewnetrznej

Volumn 104, Issue 4, 2000, Pages 695-701

  Małecki, Robert ^a  

^a Centralny Szpital Kolejowy SPZOZ   (Poland)

Author keywords

Chronic renal failure; Dialysis; Folic acid; Homocysteine

Indexed keywords

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; HUMAN; HYPERHOMOCYSTEINEMIA; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; RISK FACTORS;

EID: 6144227513     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Raine A.E.G. i wsp.: Report on management of renal failure in Europe, XXII, 1991. Nephrol. Dial. Transplant., 1992, 7 (Suppl. 2), 7.
2. Luke R.G. i wsp.: Chronic renal failure: A vasculopathic state. N. Engl. J. Med., 1998, 339, 841.
3. Zoccali C.: Cardiovascular risk in uraemic patients - is it fully explained by cassical risk factors? Nephrol. Dial. Transplant., 2000, 15, 454.
4. Folsom A. i wsp.: Prospective study of coronary heart disease in relation to fasting total homocysteine, related genetic polymorphisms, and B Vitamins. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 1998, 98, 204.
5. Stampfer M.J. i wsp.: A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA, 1992, 268, 877.
6. Yu H.H. i wsp.: Agreement among four homocysteine assays and results in patients with coronary atherosclerosis and controls. Clinical Chemistry, 2000, 46, 258.
7. Bachmann J. i wsp.: Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J. Am. Soc. Nephrol., 1995, 6, 121.
8. Manns B.J. i wsp.: Hyperhomocysteinemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. Am. J. Kidney Dis., 1999, 34, 669.
9. Dennis V.W., Robinson K.: Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int. Suppl., 1996 Dec, 57, S11-7.
10. Moustapha A. i wsp.: Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation, 1998, 97, 138.
11. Kunz K. i wsp.: Cardiovascular morbidity and endothelial dysfunction in chronic hemodialysis patients: is homocysteine the missing link? Nephrol. Dial. Transplant., 1999, 14, 34.
12. Bostom A.G., Shemin D., Verhoef P. i wsp.: Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintance dialysis patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2554.
13. Selhub J. i wsp.: Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA, 1993, 270, 2693.
14. Bostom A.G. i wsp.: Hyperhomocysteinemia and traditional cardiovascular disease risk factors in ESRD patients on dialysis: A case-control study. Atherosclerosis, 1995, 114, 93.
15. Jungers P.: Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure: a prospective study. Nephrol. Dial. Transplant., 1997, 12, 2597.
16. Manns B.J. i wsp.: Hyperhomocysteinemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. Am. J. Kidney Dis., 1999, 34, 669.
17. th Scientific Meeting of the International Society of Hypertension, June 1998, Amsterdam, Abstract: P14.30.
18. th Scientific Meeting of the International Society of Hypertension, June 1998, Amsterdam, Abstract: 5Z.2.
19. Oishi K., Nagake Y., Yamasaki H. i wsp.: The significance of serum homocysteine levels in diabetic patients on hemodialysis. Nephrol. Dial. Transplant., 2000, 15, 851.
20. Refsum H. i wsp.: Radioenzymic determination of homocysteine in plasma and urine. Clin. Chem., 1985, 31, 624.
21. Guttormsen A.B. i wsp.: Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int., 1997, 52, 495.
22. Omenn G.S. i wsp.: Preventing coronary heart disease: B vitamins and homocysteine. Circulation, 1998, 97, 421.
23. Tawakol A. i wsp.: Hyperhomocysteinemia is associated with impaired endothelial-dependent vasodilation in humans. Circulation, 1997, 95, 1119.
24. Chia-Lun Chao i wsp.: Effects of methionine-induced hyperhomocysteinemia on endothelium-dependent vasodilation and oxidative status in healthy adults. Circulation, 2000, 101, 485.
25. Chambers J.C. i wsp.: Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia an effect reversible with witamin C therapy. Circulation, 1999, 99, 1156.
26. Kanani P.M. i wsp.: Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocysteinemia in humans. Circulation, 1999, 100, 1161.
27. Robinson K. i wsp.: Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation, 1996, 94, 2743.
28. Stenvinkel P., Hiemburger O., Lindholm B. i wsp.: Are there two types of malnutrition in chronic renal failure? Evidence for relationship between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol. Dial. Transplant., 2000, 15, 953.
29. Arnadottir M.: Influence of hemodialysis on plasma total homocysteine concentration. Nephrol. Dial. Transplant., 1999, 14, 142.
30. Hultberg B. i wsp.: Plasma homocysteine in renal failure. Clin. Nephrol., 1993, 40, 230.
31. Suliman M. i wsp.: Total, free, and protein-bound sulphur amino acids in uraemic patients. Nephrol. Dial. Transplant., 1997, 12, 2332.
32. Moustapha A. i wsp.: Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Kidney Int., 1999, 55, 1470.
33. Suliman M.E., Qureshi A.R., Barany P. i wsp.: Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int., 2000, 57, 1727.
34. House A.A., Wells G.A., Donnelly J.G. i wsp.: Randomized trial of high-flux vs low-flux haemodialysis: effect on homocysteine and lipids. Nephrol. Dial. Transplant., 2000, 15, 1029.
35. den Heijer M. i wsp.: Hyperhomocysteinemia as a risk factor for Deep-Vein Thrombosis. N. Eng. J. Med., 1996, 334, 759.
36. Tamura T. i wsp.: Homocysteine, B vitamins, and vascular - access thrombosis in patients treated with hemodialysis. Am. J. Kidney Dis., 1998, 32, 475.
37. Sirrs S. i wsp.: Homocysteine and vascular access complications in hemodialysis patients: insight into a complex metabolic relationship. Nephrol. Dial. Transplant., 1999, 14, 738.
38. Ducloux D. i wsp.: Dialysis adequacy and homocysteine concentrations in peritoneal dialysis patients. Nephrol. Dial. Transplant., 1999, 14, 728.
39. Brulez H.F. i wsp.: The impact of an amino acid-based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass. Nephrol. Dial. Transplant., 1999, 14, 154.
40. Lilien M. i wsp.: Hyperhomocysteinemia in children with chronic renal failure. Nephrol. Dial. Transplant., 1999, 14, 366.
41. Litwin M., Grenda R., Cichocka E.: Hiperhomocysteinemia u dzieci z przewlekła̧, przeddializacyjna̧. niewydolnościa̧, nerek - efekt leczenia kwasem foliowym. Przegla̧d Lekarski, 1998, 55, (Suppl. 1), 140.
42. Arnadottir M. i wsp.: Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation, 1996, 61, 509.
43. Ducloux D. i wsp.: Hyperhomocysteinemia in renal transplant recipients with and without cyclosporine. Clin. Nephrol., 1998, 49, 232.
44. Fernandez-Miranda C., Gomez P., Diaz-Rubio P. i wsp.: Plasma homocysteine levels in renal transplanted patients on cyclosporine or tacrolimus therapy: effect of treatment with folic acid. Clin. Transplant., 2000, 14, 110.
45. Malinow M.R., Bostom A.G., Krauss R.M.: Homocysteine, diet, and cardiovascular diseases. A Statement for Healthcare Professionals From the Nutrition Committee, American Heart Association. Circulation, 1999, 99, 178.
46. Korzets A., Ori Y, Chagnac A. i wsp.: Erythropoietin, folic acid deficiency and hyperhomocysteinemia: is there a possible relationship in chronically hemodialyzed patients? Clin. Nephrol., 2000, 53, 48.
47. Arnadottir M. i wsp.: The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentration in dialysis patients. Clin. Nephrol., 1993, 40, 236.
48. Bostom A. i wsp.: High-dose B vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int., 1996, 49, 147.
49. Bostom A. i wsp.: Treatment of hyperhomocysteinemia in renal transplant recipients. Ann. Intern. Med., 1997, 127, 1089.
50. van Guldener C. i wsp.: No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinemia in hemodialysis patients. Nephrol. Dial. Transplant., 1998, 13, 106.
51. van Guldener C. i wsp.: Endothelium-dependent vasodilatation is impaired in peritoneal dialysis patients. Nephrol. Dial. Transplant., 1998, 13, 1782.
52. Arnadottir M. i wsp.: Treatment with different doses of folic acid in hemodialysis patients: effects on folate distribution and aminothiol concentrations. Nephrol. Dial. Transplant., 2000, 15, 524.
53. Bostom A. i wsp.: Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multiwitamin dose folic acid supplementation in renal transplant recipients. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2918.
54. Sunder-Plassmann G. i wsp.: Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: Results of the Vienna Multicenter Study. J. Am. Soc. Nephrol., 2000, 11, 1106.
55. Westhuyzen J.: Folate supplementation in the dialysis patient - fragmentary evidence and tenative recomendations. Nephrol. Dial. Transplant., 1998, 13, 2748.
56. Savage D.G., Lindenbaum J.: Neurological complications of acquired cobalamin deficiency: clinical aspects. Baillieres Clin. Haematol., 1995, 8, 657.
57. Jungers P. i wsp.: Sustained reduction of hyperhomocysteinemia with folic acid suplementation in predialysis patients. Nephrol. Dial. Transplant., 1999, 14, 2903.
58. Massy Z.A.: Reversal of hyperhomocysteinemia in chronic renal failure - is folic acid the answer? Nephrol. Dial. Transplant., 1999, 14, 2810.
59. Bostom A.G. i wsp.: Hyperhomocysteinemia and traditional cardiovascular disease risk in end-stage renal disease patients on dialysis. Atherosclerosis, 1995, 114, 93.
60. Bostom A.G. i wsp.: Short-term betaine therapy fails to lower elevated fasting total plasma homocysteine levels in hemodialysis patients maintained on chronic folic acid supplementation. Atherosclerosis, 1995, 113, 129.
61. Bostom A.G., Shemin D., Bagley P. i wsp.: Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Circulation, 2000, 101, 2829.
62. Touam M., Zingraff J., Jungers P. i wsp.: Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. Kidney Int., 1999, 56, 2292.
63. Bostom A.G.: Homocysteine: "expensive creatinine" or important, modifiable risk factor for arteriosclerotic outcomes in renal transplant recipients? J. Am. Soc. Nephrol., 2000, 11, Editorial.
64. Bergström J.: Nutrition and mortality in hemodialysis. J. Am. Soc. Nephrol., 1995, 6, 1329.